Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).
The DOI matches its Crossref record.
Abstract
5540 Background: ARIEL2 (NCT01891344) prospectively evaluated a tumor-based next-generation sequencing (NGS) LOH assay and novel algorithm to predict sensitivity to rucaparib based on BRCAmutstatus and degree of genomic LOH. Methods: Pts with measurable, platinum-sensitive HGOC were classified as BRCAmut, BRCAwt/LOHhigh (BRCA-like), or BRCAwt/LOHlow by NGS analysis of tumor tissue DNA. The primary objective of this analysis was to compare progression-free survival (PFS) of BRCAmut vs LOHhigh and LOHlow tumors. A planned post hoc analysis identified a refined genomic LOH cutoff to differentiate PFS of pts with LOHhigh vs LOHlowtumors. Results: ARIEL2 part 1 completed enrollment in December 2014; the data cutoff date was January 18, 2016. In 204 treated pts, median age was 65 years; median number of prior regimens was 1. Efficacy data are shown in the Table. The confirmed radiologic objective response rate (rORR) for germline (n=20) and somatic (n=20) BRCAmut pts was 85% and 75%, respectively. Refinement of the LOH cutoff improved median PFS and PFS HR in the LOHhigh vs LOHlowgroup. Common treatment-related AEs included nausea (71%; grade ≥3: 3%), fatigue (59%; grade ≥3: 6%), ALT/AST increased (41%; grade ≥3: 11%), and anemia (30%; grade ≥3: 19%). Three pts died due to disease progression. Conclusions: Refinement of the genomic LOH cutoff improves selection of BRCAwt/LOHhigh pts more likely to benefit from rucaparib. Clinical trial information: NCT01891344. BRCAmut Prespecified LOH Cutoff BRCAwt/LOHhigh BRCAwt/LOHlow n* 40 82 70 rORR, % 80.0 35.4† 12.9† DOR‡ 11.2 (7.4–13.7) 10.8 (5.5–12.0) 5.9 (4.6–8.5) PFS‡ 12.8 (9.0–14.7) 5.7 (5.3–7.6) 5.2 (3.6–5.5) PFS HR§ 0.27 (0.16–0.44); P<0.001 0.62 (0.42–0.90); P=0.011 − BRCAmut Refined LOH Cutoff BRCAwt/LOHhigh BRCAwt/LOHlow n* 40 69 83 rORR, % 80.0 39.1† 13.3† DOR‡ 11.2 (7.4–13.7) 10.8 (7.6–20.6) 5.7 (1.9–7.4) PFS‡ 12.8 (9.0–14.7) 7.2 (5.5–9.6) 5.0 (3.6–5.4) PFS HR§ 0.25 (0.15–0.42); P<0.001 0.51 (0.34–0.74); P<0.001 − DOR, duration of response; HR, hazard ratio. *LOH not determined for 12 pts. †Both confirmed and unconfirmed responses (RECIST v1.1). ‡Median months (95% confidence interval [CI]). §HR (95% CI) vs BRCAwt/LOHlow.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citationDelivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Lim, J., & Tan, D. S. P. (2017) · Cancers · doi:10.3390/cancers9080109 · Cited by 52
Funingana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23
Self-citation
Metadata
- Authors
- Coleman, R. L., Swisher, E. M., Oza, A. M., Scott, C. L., Giordano, H., Lin, K. K., Konecny, G. E., Tinker, A., O'Malley, D. M., Kristeleit, R. S., Ma, L., Bell-McGuinn, K. M., Brenton, J. D., Cragun, J. M., Oaknin, A., Ray-Coquard, I. L., Kaufmann, S. H., Goble, S., Maloney, L., & McNeish, I. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15_suppl
- Pages
- 5540-5540
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2737281927
- Cited by
- 33
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.5540
- The paper
- Coleman, R. L., Swisher, E. M., Oza, A. M., Scott, C. L., Giordano, H., Lin, K. K., Konecny, G. E., Tinker, A., O'Malley, D. M., Kristeleit, R. S., Ma, L., Bell-McGuinn, K. M., Brenton, J. D., Cragun, J. M., Oaknin, A., Ray-Coquard, I. L., Kaufmann, S. H., Goble, S., Maloney, L., & McNeish, I. A. (2016). Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.5540
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.